Login to Your Account

Merck, Threshold Shake Hands in $550M Cancer Collaboration

By Catherine Shaffer
Staff Writer

Monday, February 6, 2012

Stock in Threshold Pharmaceuticals Inc. surged more than 131 percent on news that it signed a deal with Merck KGaA valued at up to $550 million to develop and commercialize Threshold's cancer candidate, TH-302.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription